AMPHETAMINE SUMMARY
A single entity amphetamine product combining the neutral sulfate salts of dextroamphetamine and amphetamine, with the dextro isomer of amphetamine saccharate and d, l-amphetamine aspartate.
Attention Deficit Disorder with Hyperactivity: Adderall is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Amphetamine
Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy
subjects. [2015]
3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a popular recreational
drug. The aim of the present study was to explore the role of dopamine in the
psychotropic effects of MDMA using bupropion to inhibit the dopamine and
norepinephrine transporters through which MDMA releases dopamine and
norepinephrine by investigating.
Effect of extended-release dexmethylphenidate and mixed amphetamine salts on
sleep: a double-blind, randomized, crossover study in youth with
attention-deficit hyperactivity disorder. [2014]
measures of sleep... CONCLUSIONS: Higher stimulant doses were associated with reduced sleep duration
State dependent effect of transcranial direct current stimulation (tDCS) on
methamphetamine craving. [2014]
Transcranial direct current stimulation (tDCS) has been shown to modulate
subjective craving ratings in drug dependents by modification of cortical
excitability in dorsolateral prefrontal cortex (DLPFC). Given the mechanism of
craving in methamphetamine (meth) users, we aimed to test whether tDCS of DLPFC
could also alter self-reported craving in abstinent meth users while being
exposed to meth cues...
A randomized, controlled pilot study of MDMA (±
3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of
resistant, chronic Post-Traumatic Stress Disorder (PTSD). [2013]
Psychiatrists and psychotherapists in the US (1970s to 1985) and Switzerland
(1988-1993) used MDMA legally as a prescription drug, to enhance the
effectiveness of psychotherapy... In addition, three
MDMA sessions were more effective than two (p = 0.016).
Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse
treatment. [2013]
meaningful pattern... CONCLUSIONS: Initial smoking status did not impact treatment
Clinical Trials Related to Amphetamine
Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland [Completed]
Until positive results were found with oral naltrexone, no medication has been effective
against amphetamine dependence. The primary aim of this pilot study is to replicate the
findings of the Swedish team that showed oral Naltrexone prevented relapse to amphetamine
addiction and to extend their results by randomizing treatment-seeking amphetamine addicted
patients to a 6 month course of VIVITROL (naltrexone for extended-release injectable
suspension) or VIVITROL placebo. Patients in each group will receive drug counseling.
VIVITROL is administered monthly and may be a better test of efficacy than tablets that must
be taken daily.
A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence [Completed]
Bipolar disorder (BD) is a common and severe psychiatric illness. Drug and alcohol abuse are
very common in people with BD and other mood disorders and are associated with increased
rates of hospitalization, violence towards self and others, medication non-adherence and
cognitive impairment. However, few studies have investigated the treatment of dual-diagnosis
patients as substance use is frequently an exclusion criterion in clinical trials of
patients with BD. To address this need, we have developed a research program that explores
the pharmacotherapy of people with BD and substance related-disorders. A potentially very
interesting treatment for BD is citicoline. Some data suggest that this supplement may
stabilize mood, decrease drug use and craving, and improve memory. We found promising
results with citicoline in patients with BD and cocaine dependence. In recent years the use
of amphetamine and methamphetamine has become an important public health concern. However,
virtually no research has been conducted on the treatment of amphetamine abuse. We propose a
double-blind placebo controlled prospective trial of citicoline in a group of 60 depressed
outpatients with bipolar disorder, depressed phase or major depressive disorder and
amphetamine abuse/dependence, to explore the safety and tolerability of citicoline, and its
efficacy for mood symptoms, stimulant use and craving and its impact on cognition. Our goal
is to determine which symptoms (e. g. mood, cognition, substance use) citicoline appears to
be most effective and estimate effect sizes for future work.
Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System Compared to Placebo in Children & Adolescents With ADHD [Completed]
This study will evaluate safety and efficacy of d-Amphetamine Transdermal System for the
treatment of Attention Deficit Hyperactivity Disorder in children and adolescents.
Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD [Completed]
The study hypothesis is that dextro-amphetamine (d-amphetamine) will be safe and effective
when used to augment treatment for OCD, and that tolerance (loss of therapeutic effect) to
the medication will not develop over a period of several weeks.
Amphetamine-Enhanced Stroke Recovery [Completed]
This is an NIH Pilot Clinical Trial Grant designed to provide data to permit the rationale
design of a subsequent efficacy study. The purpose of this project is to determine the
potential benefit of amphetamine combined with physical therapy in enhancing motor recovery
in patients admitted for inpatient rehabilitation between 10 and 30 days after hemispheric
ischemic stroke. The study hypotheses are: 1, The addition of treatment with d-amphetamine
will result in at least a 12. 6 point improvement in the Fugl-Meyer motor score 3 months
after stroke. 2, There will be no clinically significant increase in the frequency of
serious adverse events associated with treatment with d-amphetamine which would preclude
further testing.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Amphetamine has an overall score of 9. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
| | Amphetamine review by 52 year old female patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Considerably Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | ADD |
| Dosage & duration: | | 30mg taken once daily for the period of 1 year |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | Elimated restless feeling and able to sleep at night. The main thing is that I do not go off the deep end when something goes wrong or that I do not control. I also had the side / added benefit of dropping fifteen pounds within the first two monhts of starting medication which also naturally makes you feel better as well. |
| Side effects: | | Taken on an empty stomach, it makes you a little jittery |
| Comments: | | My doctor recommended this course of treatment after several visits and it has worked very well for me. |
|
|
|
Page last updated: 2015-08-10
|
